This strategic shift addresses mounting concerns about regulatory compliance and workforce development in the country’s healthcare sector.
The Pharmacy and Poisons Board has approved both the 300 mg tablet and 464 mg injectable solution forms of Lenacapavir for use as pre-exposure prophylaxis (PrEP).
CS Duale demanded the swift removal of all substandard, falsified, poor-quality, counterfeit, and unregistered medicines from the Kenyan market.